PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES
    4.
    发明申请
    PYRIMIDINE ACYCLONUCLEOSIDE DERIVATIVES 审中-公开
    吡咯烷酮类衍生物衍生物

    公开(公告)号:WO1995023138A1

    公开(公告)日:1995-08-31

    申请号:PCT/KR1994000102

    申请日:1994-07-29

    CPC classification number: C07D239/56 C07D239/54

    Abstract: The present invention relates to novel pyrimidine acyclonucleoside derivatives represented by general formula (I), antiviral agents containing the derivatives as the active ingredients and processes of preparation therefor. In formula (I), R represents ethyl group or isopropyl group; R represents phenylselenenyl group, optionally substituted with one or more suitable substituents selected from C1-C3 alkyl group or halogen atom; R represents hydrogen atom, C1-C3 alkyl group, C1-C3 hydroxyalkyl group, acyloxyalkyl group, or phenyl group that is optionally substituted with one or more suitable substituents selected from C1-C3 alkyl group, C1-C3 alkoxy group or halogen atom; X represents oxygen atom or sulfur atom; and Y represents oxygen atom or methylene; with the proviso that R does not represent ethyl group when R represents phenylselenenyl group, R represents methyl group, and X and Y represent oxygen atom.

    Abstract translation: 本发明涉及由通式(I)表示的新型嘧啶阿昔洛韦衍生物,含有该衍生物作为活性成分的抗病毒剂及其制备方法。 在式(I)中,R 1表示乙基或异丙基; R 2表示苯基硒基,任选被一个或多个选自C 1 -C 3烷基或卤素原子的合适取代基取代; R 3表示氢原子,C 1 -C 3烷基,C 1 -C 3羟基烷基,酰氧基烷基或任选被一个或多个选自C 1 -C 3烷基,C 1 -C 3烷氧基或 卤素原子; X表示氧原子或硫原子; Y代表氧原子或亚甲基; 条件是当R 2表示苯基硒基时,R 1不表示乙基,R 3表示甲基,X和Y表示氧原子。

    PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES
    5.
    发明申请
    PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES 审中-公开
    生产和净化因子VIII及其衍生物的方法

    公开(公告)号:WO2008102923A1

    公开(公告)日:2008-08-28

    申请号:PCT/KR2007/000947

    申请日:2007-02-23

    CPC classification number: C07K14/755 C07K1/22

    Abstract: Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.

    Abstract translation: 公开了一种通过体外培养哺乳动物细胞产生在无血清培养基中具有因子VIII促凝血活性的蛋白质的方法,其中无血清培养基含有针对由培养细胞释放的蛋白酶的抑制剂。 根据本发明,抑制剂可以保护培养期间靶蛋白的切割并增加目标分子的均匀性,其中抑制剂可以是硫酸葡聚糖。 本发明还涉及通过亲和层析从含有靶分子和选择的抑制剂的培养基中纯化目标分子的方法。

    NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME
    7.
    发明申请
    NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME 审中-公开
    新型铂(II)复合物及其制备方法

    公开(公告)号:WO1992016539A1

    公开(公告)日:1992-10-01

    申请号:PCT/KR1991000036

    申请日:1991-12-30

    CPC classification number: C07F15/0093

    Abstract: Disclosed herein are novel platinum(II) complexe having a potent anti-tumor activity which are represented by formula (1), wherein R1 and R2, which may be the same or different, are a hydrogen atom or a C1-4 alkyl group, respectively, or jointly form a cycloalkane group together with the carbon atom attached thereto; two Xs jointly form a group represented by formula (a) or (b) wherein, R3 is a hydrogen atom or a methyl group; R4 and R5, which may be the same or different, are a hydrogen atom or a C1-4 alkyl group, respectively, or jointly form a cyclobutane together with the carbon thereto; and the absolute configurations at the respective chiral centers in the 4,5-bis(aminomethyl)-1,3-dioxolane moiety are (4R, 5R) or (4S, 5S); processes for preparing the same; and their use for treating animal or human cancer. Further, disclosed herein are novel intermediates useful for the preparation of the platinum(II) complexes and processes for preparing said intermediates.

    Abstract translation: 本文公开了具有由式(1)表示的有效抗肿瘤活性的新型铂(II)络合物,其中可以相同或不同的R 1和R 2为氢原子或C 1-4烷基, 或者与连接的碳原子一起共同形成环烷烃基; 两个X共同形成由式(a)或(b)表示的基团,其中R3是氢原子或甲基; R4和R5可以相同或不同,分别为氢原子或C1-4烷基,或与其一起共同形成环丁烷; 并且4,5-双(氨基甲基)-1,3-二氧戊环部分各手性中心的绝对构型为(4R,5R)或(4S,5S); 制备方法 及其用于治疗动物或人类癌症的用途。 此外,本文公开了可用于制备铂(II)络合物的新中间体和用于制备所述中间体的方法。

Patent Agency Ranking